HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED (China) Limited

In a report released on July 2, from UBS maintained a Buy rating on HUTCHMED (China) , with a price target of HK$34.10. The company’s shares closed...

HUTCHMED (China)  (HCM) Gets a Buy from UBS

An update from HUTCHMED (China) ( ($HK:0013) ) is now available. HUTCHMED has secured conditional approval from China’s National Medical Products A...

HUTCHMED Wins China Nod for ORPATHYS in MET-Amplified Gastric Cancer

HUTCHMED (China) ( ($HK:0013) ) has shared an announcement. HUTCHMED has reported its latest six-month blocklisting return covering the period from...

HUTCHMED Expands Share Option Capacity in Latest Blocklisting Update

In a report released on June 25, from UBS maintained a Buy rating on HUTCHMED (China) , with a price target of HK$34.10. The company’s shares close...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HCM	$11.62	+0.26%	662
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HCM	$11.62	+0.3%	662
3
4
5
6

HCM

HCM

Get HUTCHMED (China) Limited Data in Excel

Get HUTCHMED (China) Limited Data in Excel